PMV Pharmaceuticals, Inc.
PMVPHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframePMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. Valued at $69.0M, PMVP is a micro-cap name in its sector. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Market Cap
$69.0M
Beta
1.37
P/E (TTM)
—
P/E (Fwd)
-1.33
EPS (TTM)
$-1.49
EPS (Fwd)
$-0.97
ROE
-70.9%
ROA
-42.4%
Cash
$79.4M
Total Debt
$217,000
Free CF
-$43.8M
52W Change
-11.4%
Annual Financials
Cash vs Debt
Where PMVP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PMVP finished 1.56% below its 150-day moving average ($1.28) and 0.79% below its 200-day moving average ($1.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PMVP overbought or oversold?
At the September 3, 2026 close, PMVP's RSI(14) was 55.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $79.4M in cash and $217K in debt, PMVP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$43.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -70.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for PMV Pharmaceuticals, Inc. and its sector.